AU2021358274A1 - Method for treating ox40 related disease - Google Patents

Method for treating ox40 related disease Download PDF

Info

Publication number
AU2021358274A1
AU2021358274A1 AU2021358274A AU2021358274A AU2021358274A1 AU 2021358274 A1 AU2021358274 A1 AU 2021358274A1 AU 2021358274 A AU2021358274 A AU 2021358274A AU 2021358274 A AU2021358274 A AU 2021358274A AU 2021358274 A1 AU2021358274 A1 AU 2021358274A1
Authority
AU
Australia
Prior art keywords
weeks
antibody
administration
week
atopic dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021358274A
Other languages
English (en)
Other versions
AU2021358274A9 (en
Inventor
Nobuyuki Imai
Yoshinori Nagata
Kenji Ootaki
Mitsuo Sato
Munetake SHIMABE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of AU2021358274A1 publication Critical patent/AU2021358274A1/en
Publication of AU2021358274A9 publication Critical patent/AU2021358274A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021358274A 2020-10-09 2021-10-08 Method for treating ox40 related disease Pending AU2021358274A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US63/089,809 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US63/116,365 2020-11-20
US202163233592P 2021-08-16 2021-08-16
US63/233,592 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (2)

Publication Number Publication Date
AU2021358274A1 true AU2021358274A1 (en) 2023-05-25
AU2021358274A9 AU2021358274A9 (en) 2024-05-30

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021358274A Pending AU2021358274A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Country Status (11)

Country Link
US (1) US20230383001A1 (https=)
EP (1) EP4225371A4 (https=)
JP (1) JP2023545084A (https=)
KR (1) KR20230084166A (https=)
CN (1) CN116437955A (https=)
AU (1) AU2021358274A1 (https=)
CA (1) CA3198414A1 (https=)
IL (1) IL301935A (https=)
MX (1) MX2023004113A (https=)
TW (1) TW202222343A (https=)
WO (1) WO2022075476A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326123A (en) * 2023-07-25 2026-03-01 Inmagene Pte Ltd Treatment methods for alopecia areata and atopic dermatitis
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるｔ細胞の減少を抑制するために使用されるｔ細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
PT3528838T (pt) * 2016-09-23 2023-09-04 Hoffmann La Roche Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Also Published As

Publication number Publication date
AU2021358274A9 (en) 2024-05-30
TW202222343A (zh) 2022-06-16
IL301935A (en) 2023-06-01
EP4225371A1 (en) 2023-08-16
JP2023545084A (ja) 2023-10-26
KR20230084166A (ko) 2023-06-12
CN116437955A (zh) 2023-07-14
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
MX2023004113A (es) 2023-06-29
CA3198414A1 (en) 2022-04-14
US20230383001A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
TWI814575B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
WO2022075476A1 (en) Method for treating ox40 related disease
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
JP2024516698A (ja) Ｉｌｔ７結合タンパク質を使用する、自己免疫疾患の治療方法
JP2022028788A (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
US20250059290A1 (en) Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
TW202434633A (zh) 治療甲狀腺眼疾之方法
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
TWI790457B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
TW202430217A (zh) 用於免疫介導之壞死性肌病變之治療及預防的抗ｃｄ１９結合劑
WO2026078117A1 (en) Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps
US20240228644A1 (en) Treatment for systemic lupus erythematosus using anti-baffr antibodies
CN117561076A (zh) 使用ilt7结合蛋白治疗自体免疫病症的方法
CN108473576A (zh) 用于治疗复发形式的多发性硬化的方法

Legal Events

Date Code Title Description
SREP Specification republished